Lapatinib is a promising new breast cancer medication. It is an oral therapy targeting intracellular components of a receptor known as ErbB2 and a second receptor, ErbB1, which have been implicated in the growth of various tumor types. Early tests have shown excellent results in treatment of breast cancer, and researchers hope to try Lapatinib on other solid tumor cancers.
Chemical Name: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine Bis(4-methylbenzenesulfonate) monohydrate
Appearance: Yellow crystalline powder.

CAS No.: [388082-78-8]

Identification: H-1 NMR spectrum-Conforms.

Melting Point: Min240℃ (decompose)

Water:1.5%-2.5%.